Anticipated $0.11 EPS for Amphastar Pharmaceuticals, Inc. (AMPH) as of March, 11

During 2018 Q3 the big money sentiment decreased to 1. That’s change of 0.11, from 2018Q2’s 1.11. 14 investors sold all, 29 reduced holdings as Amphastar Pharmaceuticals, Inc. ratio worsened. 32 grew holdings while 11 funds bought holdings. Funds hold 20.26 million shares thus 2.33% more from 2018Q2’s 19.80 million shares.
Metropolitan Life Ny invested in 0% or 2,662 shs. 84,506 were accumulated by Millennium Management Lc. Ls Investment Limited Company reported 1,108 shs stake. Aqr Cap Management Limited Liability owns 19,663 shs. Federated Pa owns 1.28 million shs. State Street has invested 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Jacobs Levy Equity Mngmt Inc holds 0.01% or 35,325 shs in its capital. Bank Of Mellon invested 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Ameritas Investment Ptnrs reported 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Pinebridge Investments L P owns 921 shs or 0% of their US capital. Parkside Bancshares holds 40 shs. Moreover, Boston Advisors Limited Liability has 0.04% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Alliancebernstein L P, a New York-based fund reported 124,100 shs. Profund Advisors Ltd Llc invested 0.01% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). 123,581 are held by Jpmorgan Chase And Communication.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s earnings report is anticipated by WallStreet on March, 11, according to RTT. Analysts predict 10.00 % diference or $0.11 from the $0.1 EPS from 2018. This could reach $5.07 million profit for AMPH assuming the current $0.11 earnings per share will become reality. After $0.12 EPS report previous quarter, Wall Street now predicts -8.33 % negative EPS growth of Amphastar Pharmaceuticals, Inc.. The stock increased 1.70% or $0.39 during the last trading session, touching $23.35.Currently Amphastar Pharmaceuticals, Inc. is uptrending after 20.09% change in last February 12, 2018. AMPH has 114,712 shares volume. The stock outperformed the S&P 500 by 20.09%.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.The firm is worth $1.08 billion. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.Currently it has negative earnings. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

For more Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news posted briefly go to:,,, or The titles are as follows: “Amphastar: A Rising Star In The China Pharmaceutical Markets – Seeking Alpha” posted on August 08, 2018, “MannKind Negotiates Debt With Deerfield – Issues Shares In Process – Seeking Alpha” on July 13, 2018, “The Return Of OTC Asthma Inhaler Primatene Mist – Nasdaq” with a publish date: December 17, 2018, “Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene┬« MIST – GlobeNewswire” and the last “Massachusetts AG after Purdue Pharma owners for role in opioid crisis – Seeking Alpha” with publication date: January 16, 2019.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.